NO2315587T3 - - Google Patents

Info

Publication number
NO2315587T3
NO2315587T3 NO09786912A NO09786912A NO2315587T3 NO 2315587 T3 NO2315587 T3 NO 2315587T3 NO 09786912 A NO09786912 A NO 09786912A NO 09786912 A NO09786912 A NO 09786912A NO 2315587 T3 NO2315587 T3 NO 2315587T3
Authority
NO
Norway
Application number
NO09786912A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2315587(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2315587T3 publication Critical patent/NO2315587T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO09786912A 2008-08-13 2009-08-12 NO2315587T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008053252 2008-08-13
PCT/IB2009/053553 WO2010018549A2 (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan

Publications (1)

Publication Number Publication Date
NO2315587T3 true NO2315587T3 (pl) 2018-03-24

Family

ID=41346591

Family Applications (1)

Application Number Title Priority Date Filing Date
NO09786912A NO2315587T3 (pl) 2008-08-13 2009-08-12

Country Status (30)

Country Link
US (3) US8809334B2 (pl)
EP (2) EP3300729B1 (pl)
JP (3) JP5764061B2 (pl)
KR (1) KR101678699B1 (pl)
CN (1) CN102099026B (pl)
AR (1) AR073031A1 (pl)
AU (1) AU2009280843B2 (pl)
BR (1) BRPI0917661B8 (pl)
CA (1) CA2731370C (pl)
CY (2) CY1119826T1 (pl)
DK (2) DK3300729T3 (pl)
ES (2) ES2763176T3 (pl)
HK (1) HK1253355B (pl)
HR (2) HRP20171917T1 (pl)
HU (2) HUE047767T2 (pl)
IL (1) IL211143A0 (pl)
LT (2) LT3300729T (pl)
MA (1) MA32614B1 (pl)
MX (1) MX350011B (pl)
MY (1) MY178894A (pl)
NO (1) NO2315587T3 (pl)
NZ (1) NZ591601A (pl)
PL (2) PL3300729T3 (pl)
PT (2) PT3300729T (pl)
RU (1) RU2519161C2 (pl)
SI (2) SI2315587T1 (pl)
SM (2) SMT201700592T1 (pl)
TW (1) TWI446911B (pl)
WO (1) WO2010018549A2 (pl)
ZA (1) ZA201101900B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
CN104761509A (zh) 2008-02-28 2015-07-08 日本新药株式会社 纤维化抑制剂
JP5764061B2 (ja) 2008-08-13 2015-08-12 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ マシテンタン含有治療用組成物
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en) 2016-04-29 2017-10-17 Corning Optical Communications Wireless Ltd Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
MX2019006938A (es) 2016-12-14 2019-09-06 Respira Therapeutics Inc Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
AU2019339401B9 (en) * 2018-09-14 2022-11-03 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
PT3897646T (pt) 2018-12-21 2024-07-08 Actelion Pharmaceuticals Ltd Macitentano para tratamento de hipertensão arterial pulmonar
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
CA3158292A1 (en) 2019-11-29 2021-06-03 Alessandro MARESTA Methods of treating pulmonary arterial hypertension
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1097239A (en) 1976-05-11 1981-03-10 Salvador Moncada Enzymatic preparation of prostacyclin and its salts
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja) * 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
AU2002227984B8 (en) * 2000-12-18 2007-01-04 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
EP1343506A1 (de) * 2000-12-19 2003-09-17 MERCK PATENT GmbH Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate
DE10100426B4 (de) 2001-01-08 2006-04-06 Steag Hamatech Ag Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (pl) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2004017993A1 (en) * 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
CA2507334C (en) * 2002-12-02 2013-05-07 Actelion Pharmaceuticals Ltd. Pyrimidine-sulfamides and their use as endothelian receptor antagonist
US20050101608A1 (en) 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
PL2254570T3 (pl) 2008-02-20 2014-05-30 Actelion Pharmaceuticals Ltd Połączenie zawierające paklitaksel do leczenia raka jajnika
JP5764061B2 (ja) 2008-08-13 2015-08-12 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ マシテンタン含有治療用組成物

Also Published As

Publication number Publication date
NZ591601A (en) 2012-12-21
PL2315587T3 (pl) 2018-03-30
ZA201101900B (en) 2012-08-29
CN102099026A (zh) 2011-06-15
BRPI0917661B1 (pt) 2019-12-17
LT3300729T (lt) 2020-01-10
ES2763176T3 (es) 2020-05-27
US20140329824A1 (en) 2014-11-06
EP2315587A2 (en) 2011-05-04
US20110136818A1 (en) 2011-06-09
EP3300729A1 (en) 2018-04-04
MX2011001625A (es) 2011-03-29
CA2731370A1 (en) 2010-02-18
JP5956026B2 (ja) 2016-07-20
CN102099026B (zh) 2012-08-29
LT2315587T (lt) 2018-01-10
KR101678699B1 (ko) 2016-11-23
RU2519161C2 (ru) 2014-06-10
JP5956025B2 (ja) 2016-07-20
US9173881B2 (en) 2015-11-03
CY1122641T1 (el) 2021-03-12
JP2011530581A (ja) 2011-12-22
US20160022678A1 (en) 2016-01-28
US9597331B2 (en) 2017-03-21
DK2315587T3 (en) 2018-01-02
JP2015187148A (ja) 2015-10-29
MA32614B1 (fr) 2011-09-01
HRP20171917T1 (hr) 2018-02-09
HRP20192204T1 (hr) 2020-03-06
IL211143A0 (en) 2011-04-28
WO2010018549A2 (en) 2010-02-18
SI3300729T1 (sl) 2020-02-28
EP3300729B1 (en) 2019-10-09
CY1119826T1 (el) 2018-06-27
PT2315587T (pt) 2018-01-31
HUE047767T2 (hu) 2020-05-28
AR073031A1 (es) 2010-10-06
TW201010985A (en) 2010-03-16
HK1253355A1 (en) 2019-06-14
JP2015180683A (ja) 2015-10-15
KR20110045006A (ko) 2011-05-03
WO2010018549A3 (en) 2010-07-29
SI2315587T1 (en) 2018-04-30
PL3300729T3 (pl) 2020-04-30
ES2652590T3 (es) 2018-02-05
TWI446911B (zh) 2014-08-01
HUE036071T2 (hu) 2018-06-28
JP5764061B2 (ja) 2015-08-12
BRPI0917661A2 (pt) 2015-12-01
AU2009280843A1 (en) 2010-02-18
US8809334B2 (en) 2014-08-19
BRPI0917661B8 (pt) 2021-05-25
MY178894A (en) 2020-10-21
MX350011B (es) 2017-08-22
SMT201700592T1 (it) 2018-03-08
EP2315587B1 (en) 2017-10-25
SMT201900740T1 (it) 2020-01-14
DK3300729T3 (da) 2020-01-20
AU2009280843B2 (en) 2015-03-05
PT3300729T (pt) 2020-01-20
RU2011109084A (ru) 2012-09-20
HK1253355B (en) 2020-06-19
CA2731370C (en) 2017-03-14

Similar Documents

Publication Publication Date Title
BRPI0909040A2 (pl)
BRPI0917573A2 (pl)
BRPI0908549B8 (pl)
BRPI0918697A2 (pl)
BRPI0917525A2 (pl)
BRPI0920750A2 (pl)
BRPI0919470A2 (pl)
BRPI0907698A2 (pl)
BRPI0917618A8 (pl)
BRPI0922455A2 (pl)
BRPI0923734A2 (pl)
BRPI0912727A2 (pl)
BRPI0922669A2 (pl)
BRPI0908285A2 (pl)
BRPI0910485A2 (pl)
BRPI0914750A2 (pl)
BRPI0919811A2 (pl)
BRPI0915616A2 (pl)
BRPI0908120A2 (pl)
BRPI0912462A2 (pl)
BRPI0904541A8 (pl)
BRPI0920914A2 (pl)
BRPI0922550A2 (pl)
BRPI0916284A2 (pl)
BRPI0911617A2 (pl)